AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15462619 — intervention group
Group type: COMPARATOR
Intervention: Repeatedly passed safely
Number of subjects: 0
Study 11443189 — intervention group
Group type: EXPERIMENTAL
Intervention: leuprolide with ipriflavone
Number of subjects: 102
Study 11443189 — intervention group
Group type: COMPARATOR
Intervention: leuprolide only
Number of subjects: 102
Study 9223362 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-blood cardioplegia containing 1 mM adenosine
Number of subjects: 61
Study 9223362 — intervention group
Group type: COMPARATOR
Intervention: Placebo (standard cold-blood cardioplegia)
Number of subjects: 61
Study 9223362 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 microM adenosine)
Number of subjects: 61
Study 7958119 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized salbutamol (200 micrograms)
Number of subjects: 10
Study 7958119 — intervention group
Group type: COMPARATOR
Intervention: Combination dose aerosol of fenoterol hydrobromide (200 micrograms) and ipratropium bromide (80 micrograms)
Number of subjects: 10
Study 3314464 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg administered twice daily
Number of subjects: 36
Study 3314464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 31530820 — intervention group
Group type: EXPERIMENTAL
Intervention: Group OA (obesity patients with metabolic diseases)
Number of subjects: 1914
Study 31530820 — intervention group
Group type: EXPERIMENTAL
Intervention: Group O (obesity patients without metabolic diseases)
Number of subjects: 1914
Study 31530820 — intervention group
Group type: EXPERIMENTAL
Intervention: Group OA
Number of subjects: 1914
Study 31530820 — intervention group
Group type: EXPERIMENTAL
Intervention: Common biomarkers for obesity patients with high uric acid, high serum lipids, and high blood pressure
Number of subjects: 1914
Study 31530820 — intervention group
Group type: EXPERIMENTAL
Intervention: Blautia, Romboutsia, Ruminococcus2, Clostridium sensu stricto, Dorea
Number of subjects: 1914
Study 31530820 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteroides, Roseburia, Butyricicoccus, Alistipes, Parasutterella, Parabacteroides, Clostridium IV
Number of subjects: 1914
Study 29946969 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive jumps countermeasure (JUMP)
Number of subjects: 22
Study 29946969 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTRL)
Number of subjects: 22
Study 26573073 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic minocycline (100 mg twice per day for 4 weeks)
Number of subjects: 150
Study 26573073 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive treatment (after rash developed, per grade of rash)
Number of subjects: 150
Study 26573073 — intervention group
Group type: COMPARATOR
Intervention: No treatment unless severe (grade 3)
Number of subjects: 150
Study 24496086 — intervention group
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block (SGB) with 5 mL of 0.5% bupivacaine
Number of subjects: 40
Study 24496086 — intervention group
Group type: COMPARATOR
Intervention: Sham injection of saline
Number of subjects: 40
Study 22562434 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) with long-chain triglycerides (LCTs)
Number of subjects: 50
Study 22562434 — intervention group
Group type: COMPARATOR
Intervention: LCTs plus medium-chain triglycerides (MCTs) as 50/50
Number of subjects: 50
Study 22562434 — intervention group
Group type: EXPERIMENTAL
Intervention: LCTs
Number of subjects: 50
Study 20173436 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg ketamine
Number of subjects: 60
Study 20173436 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 60
Study 18073339 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel intervention promoting physical activity and healthy eating
Number of subjects: 0
Study 18073339 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadership involvement through key informant interviews and advisory boards
Number of subjects: 0
Study 18073339 — intervention group
Group type: EXPERIMENTAL
Intervention: Employee focus groups and advisory boards
Number of subjects: 0
Study 18073339 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative environmental assessments
Number of subjects: 0
Study 15704506 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week home-based trunk-strengthening exercise programme
Number of subjects: 28
Study 15704506 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 28
Study 12235653 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy (100 g/day)
Number of subjects: 11
Study 12235653 — intervention group
Group type: EXPERIMENTAL
Intervention: Tea extract (3 g/day)
Number of subjects: 11
Study 12235653 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetables (400 g/day as 134 g broccoli, 134 g brussels sprouts, and 134 g petits pois)
Number of subjects: 11
Study 12235653 — intervention group
Group type: COMPARATOR
Intervention: High red meat diet (420 g/day)
Number of subjects: 11
Study 10460065 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (200 mL, double-strength, three times a day for 2 days) with atorvastatin (40 mg)
Number of subjects: 23
Study 10460065 — intervention group
Group type: EXPERIMENTAL
Intervention: Grapefruit juice (200 mL, double-strength, three times a day for 2 days) with pravastatin (40 mg)
Number of subjects: 23
Study 7543131 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet advice (D, n = 40)
Number of subjects: 157
Study 7543131 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise advice (E, n = 39)
Number of subjects: 157
Study 7543131 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of diet and exercise advice (DE, n = 39)
Number of subjects: 157
Study 7543131 — intervention group
Group type: COMPARATOR
Intervention: Control group (C, n = 39)
Number of subjects: 157
Study 2523528 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg triamcinolone diacetate (TR)
Number of subjects: 22
Study 2523528 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg of preservative-free morphine (MP)
Number of subjects: 22
Study 2523528 — intervention group
Group type: EXPERIMENTAL
Intervention: Both triamcinolone and morphine (TR and MP)
Number of subjects: 22
Study 974610 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (beta-blocking agent)
Number of subjects: 21
Study 974610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31373537 — intervention group
Group type: COMPARATOR
Intervention: TG1050 (109, 1010, 1011 virus particles)
Number of subjects: 48
Study 31373537 — intervention group
Group type: EXPERIMENTAL
Intervention: TG1050 (1010 virus particles)
Number of subjects: 48
Study 31373537 — intervention group
Group type: COMPARATOR
Intervention: TG1050
Number of subjects: 48
Study 31402112 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical and oral antibiotic bowel preparation (MOABP)
Number of subjects: 396
Study 31402112 — intervention group
Group type: COMPARATOR
Intervention: No bowel preparation (NBP)
Number of subjects: 396
Study 28655522 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus pravastatin
Number of subjects: 3397
Study 28655522 — intervention group
Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 3397
Study 25751506 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal WIV vaccine (sWIV) - one dose
Number of subjects: 0
Study 25751506 — intervention group
Group type: EXPERIMENTAL
Intervention: Pandemic WIV vaccine (pWIV) - two doses
Number of subjects: 0
Study 25751506 — intervention group
Group type: COMPARATOR
Intervention: Commercially available trivalent comparator vaccine - one dose followed by placebo
Number of subjects: 0
Study 23395192 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Social Skills Training (CBSST)
Number of subjects: 79
Study 23395192 — intervention group
Group type: COMPARATOR
Intervention: Goal-Focused Supportive Contact (GFSC)
Number of subjects: 79
Study 21954992 — intervention group
Group type: EXPERIMENTAL
Intervention: GP ablation plus PVI or Maze
Number of subjects: 342
Study 21954992 — intervention group
Group type: EXPERIMENTAL
Intervention: GP ablation alone
Number of subjects: 342
Study 19203569 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg test formulation of risperidone
Number of subjects: 30
Study 19203569 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg test formulation of risperidone
Number of subjects: 30
Study 19203569 — intervention group
Group type: COMPARATOR
Intervention: 1 mg reference formulation of risperidone
Number of subjects: 30
Study 19203569 — intervention group
Group type: COMPARATOR
Intervention: 2 mg reference formulation of risperidone
Number of subjects: 30
Study 17540193 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide (28-day continuous infusion)
Number of subjects: 120
Study 17540193 — intervention group
Group type: COMPARATOR
Intervention: Placebo (28-day continuous infusion)
Number of subjects: 120
Study 17540193 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 120
Study 16734116 — intervention group
Group type: EXPERIMENTAL
Intervention: S. mansoni calreticulin (SmCaR)
Number of subjects: 30
Study 16734116 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble adult worm antigen (SAWA)
Number of subjects: 30
Study 15213581 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate alone
Number of subjects: 103
Study 15213581 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate plus psychosocial treatment (parent training, counseling, social skills training, psychotherapy, academic assistance)
Number of subjects: 103
Study 15213581 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate plus attention psychosocial control treatment
Number of subjects: 103
Study 11181810 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine (0.2 mg twice a day)
Number of subjects: 15
Study 11181810 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 9164420 — intervention group
Group type: EXPERIMENTAL
Intervention: Befunolol
Number of subjects: 10
Study 9164420 — intervention group
Group type: EXPERIMENTAL
Intervention: Metipranolol
Number of subjects: 10
Study 9164420 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 10
Study 9164420 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 10
Study 9164420 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipivefrin
Number of subjects: 10
Study 9164420 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 10
Study 9164420 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobunolol
Number of subjects: 10
Study 9164420 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilocarpine
Number of subjects: 10
Study 8220653 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg fluoxetine (FXT)
Number of subjects: 38
Study 8220653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 8220653 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) breakfast (80 g maltodextrin, 300 kcal)
Number of subjects: 38
Study 8220653 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-rich (PROT) breakfast (60% milk protein and 40% CHO, 300 kcal)
Number of subjects: 38
Study 3114812 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of physostigmine for 2 h
Number of subjects: 10
Study 3114812 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic glucose)
Number of subjects: 10
Study 30071838 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of at least three different classes of psychiatric drugs
Number of subjects: 1653
Study 30071838 — intervention group
Group type: COMPARATOR
Intervention: FGA alone therapy
Number of subjects: 1653
Study 30071838 — intervention group
Group type: COMPARATOR
Intervention: SGA use
Number of subjects: 1653
Study 30071838 — intervention group
Group type: COMPARATOR
Intervention: Combination of drugs from two different classes
Number of subjects: 1653
Study 26919829 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic upper limb pain group
Number of subjects: 82
Study 26919829 — intervention group
Group type: COMPARATOR
Intervention: Pain-free controls
Number of subjects: 82
Study 25664643 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive skill-based intervention
Number of subjects: 130
Study 25664643 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity intervention
Number of subjects: 130
Study 25664643 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship education programs
Number of subjects: 130
Study 23845658 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 75
Study 23845658 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 75
Study 21384106 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg caffeine
Number of subjects: 20
Study 21384106 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/kg caffeine
Number of subjects: 20
Study 18417099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 46
Study 18417099 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone
Number of subjects: 46
Study 18417099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 16847198 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoralen-UV-A (PUVA) therapy
Number of subjects: 93
Study 16847198 — intervention group
Group type: COMPARATOR
Intervention: Narrowband UV-B (NB-UVB) therapy
Number of subjects: 93
Study 12700623 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary advice to increase Mediterranean food consumption
Number of subjects: 11323
Study 11094366 — intervention group
Group type: EXPERIMENTAL
Intervention: Jones jig appliance
Number of subjects: 72
Study 11094366 — intervention group
Group type: COMPARATOR
Intervention: Cervical headgear
Number of subjects: 72
Study 8636825 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐24ACTH stimulation testing (0.1 microgram/kg)
Number of subjects: 67
Study 8636825 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐24ACTH stimulation testing (0.2 microgram/kg)
Number of subjects: 67
Study 8636825 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline cortisol concentrations < 414 nmol/L (15.0 micrograms/dl)
Number of subjects: 67
Study 8636825 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to 1‐24ACTH
Number of subjects: 67
Study 1473127 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (15 ml/d, equivalent to 3.1 g of n-3 fatty acid per day)
Number of subjects: 20
Study 1473127 — intervention group
Group type: COMPARATOR
Intervention: Placebo (15 ml/d saline)
Number of subjects: 20
Study 1473127 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil
Number of subjects: 20
Study 1473127 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6741670 — intervention group
Group type: EXPERIMENTAL
Intervention: Female smokers during separate and combined presentation of distractors
Number of subjects: 0
Study 6741670 — intervention group
Group type: EXPERIMENTAL
Intervention: Female smokers during task-induced distraction
Number of subjects: 0
Study 6741670 — intervention group
Group type: EXPERIMENTAL
Intervention: Task and combined noise- and task-induced distraction
Number of subjects: 0
Study 31087608 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut consumption (48g walnuts in a smoothie)
Number of subjects: 10
Study 31087608 — intervention group
Group type: COMPARATOR
Intervention: Placebo smoothie (macronutrient-matched without nuts)
Number of subjects: 10
Study 28931520 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg HIV-MAG DNA vaccine coadministered with pIL-12 at 0, 250, 1,000, or 1,500 μg
Number of subjects: 100
Study 28931520 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg HIV-MAG DNA vaccine coadministered with pIL-12 at low and medium doses
Number of subjects: 100
Study 28931520 — intervention group
Group type: EXPERIMENTAL
Intervention: VSV-Gag vaccine boost
Number of subjects: 100
Study 28931520 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA prime with high-dose pIL-12
Number of subjects: 100
Study 28931520 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose pIL-12 with DNA prime
Number of subjects: 100
Study 25204714 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical lidocaine
Number of subjects: 25
Study 25204714 — intervention group
Group type: COMPARATOR
Intervention: Nonanesthetized condition
Number of subjects: 25
Study 23325716 — intervention group
Group type: COMPARATOR
Intervention: Control condition (CON)
Number of subjects: 9
Study 23325716 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise protocol (EP)
Number of subjects: 9
Study 21411093 — intervention group
Group type: EXPERIMENTAL
Intervention: bezafibrate
Number of subjects: 14
Study 21411093 — intervention group
Group type: EXPERIMENTAL
Intervention: fenofibrate
Number of subjects: 14
Study 18775100 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed-derived lignan capsules (360 mg/d)
Number of subjects: 70
Study 18775100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 17243014 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered targeted group intervention (n=36), 6 sessions of 90 minutes each
Number of subjects: 73
Study 17243014 — intervention group
Group type: COMPARATOR
Intervention: Delayed treatment control group (n=37)
Number of subjects: 73
Study 15770057 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozonated autohemotherapy (ozone concentration of 50 microg/ml)
Number of subjects: 12
Study 15770057 — intervention group
Group type: COMPARATOR
Intervention: Control autohemotherapy (blood exposure to oxygen)
Number of subjects: 12
Study 12099928 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) breathing at 2.8 ATA for 15 min
Number of subjects: 16
Study 12099928 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric oxygen (NBO) breathing
Number of subjects: 16
Study 12099928 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) breathing
Number of subjects: 16
Study 10453777 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychophysical testing (PT)
Number of subjects: 100
Study 10453777 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal adductor reflex (LAR)
Number of subjects: 100
Study 10453777 — intervention group
Group type: EXPERIMENTAL
Intervention: Total sample
Number of subjects: 100
Study 7799018 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel administered at 135 mg/m2 by 3-hour infusion
Number of subjects: 30
Study 7799018 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel administered at 175 mg/m2 by 24-hour infusion
Number of subjects: 30
Study 7799018 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel administered at 225 mg/m2 by 3-hour infusion
Number of subjects: 30
Study 7799018 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration that plasma concentrations of paclitaxel > or = 0.05 mumol/L
Number of subjects: 30
Study 7799018 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic model for paclitaxel disposition
Number of subjects: 30
Study 2402844 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous oestradiol for four months supplemented by medroxyprogesterone (Perlutex) from the 12th to 26th day of every month
Number of subjects: 34
Study 2402844 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous oestradiol treatment
Number of subjects: 34
Study 380533 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a 0.5-mm larger trephine on the donor
Number of subjects: 46
Study 380533 — intervention group
Group type: COMPARATOR
Intervention: Same size trephine on both donor and recipient
Number of subjects: 46
Study 6859585 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous-oxide-isoflurane (0.75-1.5% inspired)
Number of subjects: 20
Study 6859585 — intervention group
Group type: COMPARATOR
Intervention: Nitrous-oxide-fentanyl
Number of subjects: 20
Study 31086034 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 g enzymatically hydrolyzed collagen protein (EHC)
Number of subjects: 10
Study 31086034 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 g non-enzymatically hydrolyzed collagen protein (NC)
Number of subjects: 10
Study 31086034 — intervention group
Group type: COMPARATOR
Intervention: Placebo (250 mL water)
Number of subjects: 10
Study 30440816 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep sleep intervention
Number of subjects: 14
Study 30440816 — intervention group
Group type: EXPERIMENTAL
Intervention: Shallow sleep intervention
Number of subjects: 14
Study 30440816 — intervention group
Group type: COMPARATOR
Intervention: Non‐intervention
Number of subjects: 14
Study 27085834 — intervention group
Group type: EXPERIMENTAL
Intervention: LASMIV with delivery of the testis and ligature of collateral and gubernacular veins
Number of subjects: 70
Study 27085834 — intervention group
Group type: COMPARATOR
Intervention: LASMIV without delivery of the testis
Number of subjects: 70
Study 25456576 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) - 3 cycles of cuff inflation to 200 mm Hg for 5 min, separated by 5 min deflation intervals.
Number of subjects: 60
Study 25456576 — intervention group
Group type: COMPARATOR
Intervention: Control group - blood pressure cuff remained deflated.
Number of subjects: 60
Study 23046782 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CT)
Number of subjects: 132
Study 23046782 — intervention group
Group type: COMPARATOR
Intervention: Acceptance and Commitment Therapy (ACT)
Number of subjects: 132
Study 20487354 — intervention group
Group type: EXPERIMENTAL
Intervention: Female-specific psychosocial intervention
Number of subjects: 29
Study 20487354 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 29
Study 19147974 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity and exercise level assessed by questionnaire, maximum strength of the legs and aerobic capacity
Number of subjects: 299
Study 19147974 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-grip strength
Number of subjects: 299
Study 19147974 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight
Number of subjects: 299
Study 19147974 — intervention group
Group type: EXPERIMENTAL
Intervention: Lean body mass
Number of subjects: 299
Study 19147974 — intervention group
Group type: EXPERIMENTAL
Intervention: Habitual physical activity
Number of subjects: 299
Study 15702199 — intervention group
Group type: EXPERIMENTAL
Intervention: Independence estimating equations (IEE)
Number of subjects: 0